Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.41 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.41 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.41 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.41 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11369388 | 0.94 | PTGS2 (0.47) | TTRCYP2C9USP2LMNATBXA2R | |
| SCHEMBL11373541 | 0.89 | KMT2A (0.39) | TTRCYP2C9USP2LMNATBXA2R | |
| SCHEMBL6950571 | 0.85 | TTR (0.67) | TTRCYP2C9USP2LMNATBXA2R | |
| SCHEMBL13800457 | 0.85 | TTR (0.67) | TTRCYP2C9USP2LMNATBXA2R | |
| SCHEMBL11376850 | 0.82 | TTR (0.53) | TTRCYP2C9USP2LMNATBXA2R | |
| SCHEMBL4450148 | 0.82 | TTR (0.48) | TTRCYP2C9USP2LMNATBXA2R | |
| SCHEMBL11366136 | 0.81 | TTR (0.50) | TTRCYP2C9USP2LMNATBXA2R | |
| SCHEMBL11406525 | 0.80 | TTR (0.50) | TTRCYP2C9USP2LMNATBXA2R | |
| SCHEMBL11376343 | 0.80 | TTR (0.56) | TTRCYP2C9USP2LMNATBXA2R | |
| SCHEMBL4443753 | 0.79 | TTR (0.45) | TTRCYP2C9USP2LMNATBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638567-B1 | COMPOSITION COMPRISING A PULMONARY SURFACTANT AND SILDENAFIL FOR THE TREATMENT OF LUNG DISEASES | NYCOMED GMBH (DE) | 2012-02-29 | — | — | EP | disclosed |
| US-7247317-B2 | Compositions comprising phenylaminothiophenacetic acid derivatives for the treatment of acute or adult respiratory distress syndrome (ARDS) and infant respiratory distress syndrome (IRDS) | ALTANA PHARMA AG (DE) | 2007-07-24 | — | — | US | disclosed |
| US-7238664-B2 | Composition comprising a pulmonary surfactant and a PDE5 inhibitor for the treatment of lung diseases | ALTANA PHARMA AG (DE) | 2007-07-03 | — | — | US | disclosed |
| US-20060148693-A1 | Composition comprising a pulmonary surfactant and a pde5 inhibitor for the treatment of lung diseases | ALTANA PHARMA AG (DE) | 2006-07-06 | — | — | US | disclosed |
| EP-1638567-A1 | COMPOSITION COMPRISING A PULMONARY SURFACTANT AND A PDE5 INHIBITOR FOR THE TREATMENT OF LUNG DISEASES | ALTANA Pharma AG (DE) | 2006-03-29 | — | — | EP | disclosed |
| US-6858223-B2 | Compositions comprising phenylaminothiophenacetic acid derivatives for the treatment of acute or adult respiratory distress syndrome (ARDS) and infant respiratory distress syndrome (IRDS) | ALTANA PHARMA AG (DE) | 2005-02-22 | — | — | US | disclosed |
| WO-2004110450-A1 | COMPOSITION COMPRISING A PULMONARY SURFACTANT AND A PDE5 INHIBITOR FOR THE TREATMENT OF LUNG DISEASES | ALTANA PHARMA AG (DE) | 2004-12-23 | — | — | WO | disclosed |
| US-20040198664-A1 | Compositions comprising phenylaminothiophenacetic acid derivatives for the treatment of acute or adult respiratory distress syndrome (ARDS) and infant respiratory distress syndrome (IRDS) | ALTANA PHARMA AG. | 2004-10-07 | — | — | US | disclosed |
| US-20040192600-A1 | Combination of selective cox-2 inhibitor and lung surfactant for respiratory syndrome | ALTANA PHARMA AG (DE) | 2004-09-30 | — | — | US | disclosed |
| EP-1414484-A1 | COMBINATION OF SELECTIVE COX-2 INHIBITOR AND LUNG SURFACTANT FOR RESPIRATORY SYNDROME | ALTANA Pharma AG (DE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003011316-A1 | COMBINATION OF SELECTIVE COX-2 INHIBITOR AND LUNG SURFACTANT FOR RESPIRATORY SYNDROME | ALTANA PHARMA AG (DE) | 2003-02-13 | — | — | WO | disclosed |
| US-20030007931-A1 | Compositions comprising phenylaminothiophenacetic acid derivatives for the treatment of acute or adult respiratory distress syndrome (ARDS) and infant respiratory distress syndrome (IRDS) | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH | 2003-01-09 | — | — | US | disclosed |
| EP-1098645-B1 | COMPOSITIONS COMPRISING PHENYLAMINOTHIOPHENACETIC ACID DERIVATIVES FOR THE TREATMENT OF ACUTE OR ADULT RESPIRATORY DISTRESS SYNDROME (ARDS) AND INFANT RESPIRATORY DISTRESS SYNDROME (IRDS) | ALTANA PHARMA AG (DE) | 2002-11-20 | — | — | EP | disclosed |
| EP-1098645-A1 | COMPOSITIONS COMPRISING PHENYLAMINOTHIOPHENACETIC ACID DERIVATIVES FOR THE TREATMENT OF ACUTE OR ADULT RESPIRATORY DISTRESS SYNDROME (ARDS) AND INFANT RESPIRATORY DISTRESS SYNDROME (IRDS) | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2001-05-16 | — | — | EP | disclosed |
| WO-1999066926-A1 | COMPOSITIONS COMPRISING PHENYLAMINOTHIOPHENACETIC ACID DERIVATIVES FOR THE TREATMENT OF ACUTE OR ADULT RESPIRATORY DISTRESS SYNDROME (ARDS) AND INFANT RESPIRATORY DISTRESS SYNDROME (IRDS) | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1999-12-29 | — | — | WO | disclosed |
| US-4272507-A | Phenylaminothiophenacetic acids, their synthesis, compositions and use | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1981-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030007931-A1 | Compositions comprising phenylaminothiophenacetic acid derivatives for the treatment of acute or adult respiratory distress syndrome (ARDS) and infant respiratory distress syndrome (IRDS) | HRAS, HRH2, HRH1 | TTR 969/4885CYP2C9 3584/4885USP2 2785/4885 |
| US-20040198664-A1 | Compositions comprising phenylaminothiophenacetic acid derivatives for the treatment of acute or adult respiratory distress syndrome (ARDS) and infant respiratory distress syndrome (IRDS) | HRAS, HRH1, HRH2 | TTR 1499/4885CYP2C9 3740/4885USP2 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.